Edgewise Therapeutics Future Growth
Future criteria checks 0/6
Edgewise Therapeutics is forecast to grow earnings and revenue by 3.5% and 75% per annum respectively. EPS is expected to grow by 12.9% per annum. Return on equity is forecast to be -30.8% in 3 years.
Key information
3.5%
Earnings growth rate
12.9%
EPS growth rate
| Pharmaceuticals earnings growth | 27.6% |
| Revenue growth rate | 75.0% |
| Future return on equity | -30.8% |
| Analyst coverage | Good |
| Last updated | 21 Jun 2024 |
Recent future growth updates
Recent updates
Edgewise: Intriguing Drug Candidate, But Consider Selling After Recent Run
May 10We're Not Very Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Rate
May 10
Edgewise Therapeutics: Behind The Massive Rally
Feb 18Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth
Dec 07Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans
Aug 16Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth
Apr 28We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth
Jan 13Edgewise Therapeutics proposes $100M stock offering plan
Sep 13Edgewise Therapeutics GAAP EPS of -$0.32 beats by $0.02
Aug 04Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth
Aug 02We're Hopeful That Edgewise Therapeutics (NASDAQ:EWTX) Will Use Its Cash Wisely
Mar 24We're Hopeful That Edgewise Therapeutics (NASDAQ:EWTX) Will Use Its Cash Wisely
Nov 23Edgewise Therapeutics names new chief medical officer
Apr 27Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 12 | -184 | N/A | N/A | 4 |
| 12/31/2025 | N/A | -178 | -107 | -105 | 6 |
| 12/31/2024 | N/A | -132 | -86 | -84 | 6 |
| 3/31/2024 | N/A | -106 | -99 | -98 | N/A |
| 12/31/2023 | N/A | -100 | -98 | -92 | N/A |
| 9/30/2023 | N/A | -89 | -86 | -77 | N/A |
| 6/30/2023 | N/A | -81 | -77 | -67 | N/A |
| 3/31/2023 | N/A | -76 | -72 | -63 | N/A |
| 12/31/2022 | N/A | -68 | -58 | -53 | N/A |
| 9/30/2022 | N/A | -61 | -53 | -50 | N/A |
| 6/30/2022 | N/A | -56 | -48 | -46 | N/A |
| 3/31/2022 | N/A | -51 | -41 | -40 | N/A |
| 12/31/2021 | N/A | -43 | -34 | -34 | N/A |
| 9/30/2021 | N/A | -36 | -29 | -29 | N/A |
| 6/30/2021 | N/A | -27 | -24 | -24 | N/A |
| 3/31/2021 | N/A | -21 | -18 | -18 | N/A |
| 12/31/2020 | N/A | -17 | -15 | -15 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EWTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: EWTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: EWTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: EWTX is forecast to have no revenue next year.
High Growth Revenue: EWTX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: EWTX is forecast to be unprofitable in 3 years.